Trending Stock News

Miller Inds Tenn (MLR) Valuation Declined While Olstein Capital Management LP Trimmed Stake; As Immunogen (IMGN) Stock Price Rose, Baker Bros Advisors LP Trimmed Position by $750,000

ImmunoGen, Inc. (NASDAQ:IMGN) Logo

Olstein Capital Management Lp decreased its stake in Miller Inds Inc Tenn (MLR) by 15.09% based on its latest 2017Q4 regulatory filing with the SEC. Olstein Capital Management Lp sold 12,520 shares as the company’s stock declined 0.79% with the market. The institutional investor held 70,426 shares of the capital goods company at the end of 2017Q4, valued at $1.82M, down from 82,946 at the end of the previous reported quarter. Olstein Capital Management Lp who had been investing in Miller Inds Inc Tenn for a number of months, seems to be less bullish one the $298.55 million market cap company. The stock increased 2.24% or $0.58 during the last trading session, reaching $26.23. About 10,768 shares traded. Miller Industries, Inc. (NYSE:MLR) has risen 0.60% since April 16, 2017 and is uptrending. It has underperformed by 10.95% the S&P500.

Julian Baker decreased its stake in Immunogen Inc. (IMGN) by 4.65% based on its latest 2017Q4 regulatory filing with the SEC. Baker Bros Advisors Lp sold 125,000 shares as the company’s stock rose 69.65% while stock markets declined. The hedge fund run by Julian Baker held 2.56 million shares of the health care company at the end of 2017Q4, valued at $16.43M, down from 2.69M at the end of the previous reported quarter. Baker Bros Advisors Lp who had been investing in Immunogen Inc. for a number of months, seems to be less bullish one the $1.37 billion market cap company. The stock increased 1.94% or $0.2 during the last trading session, reaching $10.3. About 992,857 shares traded. ImmunoGen, Inc. (NASDAQ:IMGN) has risen 195.97% since April 16, 2017 and is uptrending. It has outperformed by 184.42% the S&P500.

Investors sentiment increased to 1.38 in 2017 Q4. Its up 0.22, from 1.16 in 2017Q3. It is positive, as 26 investors sold IMGN shares while 39 reduced holdings. 37 funds opened positions while 53 raised stakes. 101.53 million shares or 15.77% more from 87.70 million shares in 2017Q3 were reported. Hall Laurie J Trustee invested in 0% or 380 shares. Paloma Ptnrs Mngmt holds 38,838 shares. Tci Wealth has 0.01% invested in ImmunoGen, Inc. (NASDAQ:IMGN). Nuveen Asset Mngmt Ltd Liability Com has invested 0% of its portfolio in ImmunoGen, Inc. (NASDAQ:IMGN). Lazard Asset Mngmt Ltd reported 0% of its portfolio in ImmunoGen, Inc. (NASDAQ:IMGN). Renaissance Techs Limited owns 1.09 million shares for 0.01% of their portfolio. Credit Suisse Ag accumulated 127,793 shares. Axa reported 181,400 shares. Da Davidson & reported 93,349 shares. Oppenheimer Asset reported 0% of its portfolio in ImmunoGen, Inc. (NASDAQ:IMGN). Balyasny Asset Mgmt Limited Liability Corporation holds 24,978 shares. Ubs Asset Americas reported 0% stake. Twin Focus Capital Prns Ltd Llc holds 0.37% or 113,216 shares. Gsa Cap Partners Llp accumulated 270,434 shares. Primecap Ca holds 0.02% of its portfolio in ImmunoGen, Inc. (NASDAQ:IMGN) for 3.82M shares.

Since February 13, 2018, it had 0 insider buys, and 12 selling transactions for $3.27 million activity. On Wednesday, February 21 the insider JUNIUS DANIEL M sold $140,556. On Wednesday, February 21 Ryll Thomas sold $129,211 worth of ImmunoGen, Inc. (NASDAQ:IMGN) or 11,876 shares. The insider Gregory Richard J. sold $375,208. Another trade for 11,379 shares valued at $123,804 was made by Wingrove Theresa on Wednesday, February 21. Another trade for 67,717 shares valued at $736,084 was sold by Enyedy Mark J. BARROWS CRAIG also sold $168,618 worth of ImmunoGen, Inc. (NASDAQ:IMGN) on Wednesday, February 21.

Among 9 analysts covering Immunogen (NASDAQ:IMGN), 6 have Buy rating, 1 Sell and 2 Hold. Therefore 67% are positive. Immunogen had 31 analyst reports since August 3, 2015 according to SRatingsIntel. Jefferies upgraded ImmunoGen, Inc. (NASDAQ:IMGN) on Wednesday, November 25 to “Buy” rating. The firm has “Buy” rating given on Tuesday, August 29 by Leerink Swann. The firm has “Hold” rating by Cantor Fitzgerald given on Tuesday, May 30. Jefferies maintained it with “Buy” rating and $900 target in Sunday, August 6 report. On Wednesday, July 29 the stock rating was maintained by Oppenheimer with “Outperform”. The stock of ImmunoGen, Inc. (NASDAQ:IMGN) has “Underweight” rating given on Monday, September 21 by Morgan Stanley. The company was downgraded on Monday, August 3 by Cantor Fitzgerald. The company was maintained on Monday, July 27 by RBC Capital Markets. On Monday, June 26 the stock rating was maintained by Jefferies with “Buy”. Cantor Fitzgerald maintained ImmunoGen, Inc. (NASDAQ:IMGN) on Tuesday, August 29 with “Hold” rating.

Baker Bros Advisors Lp, which manages about $8.20 billion and $11.54B US Long portfolio, upped its stake in Neurocrine Biosciences Inc. (NASDAQ:NBIX) by 387,942 shares to 1.00M shares, valued at $77.95M in 2017Q4, according to the filing. It also increased its holding in Assembly Biosciences Inc. (NASDAQ:ASMB) by 72,727 shares in the quarter, for a total of 322,727 shares, and has risen its stake in Heron Therapeutics Inc. (NASDAQ:HRTX).

Olstein Capital Management Lp, which manages about $769.90 million and $785.28 million US Long portfolio, upped its stake in Aon Plc (NYSE:AON) by 9,000 shares to 53,000 shares, valued at $7.10 million in 2017Q4, according to the filing. It also increased its holding in Intel Corp (NASDAQ:INTC) by 233,000 shares in the quarter, for a total of 386,000 shares, and has risen its stake in Hologic Inc (NASDAQ:HOLX).

ImmunoGen, Inc. (NASDAQ:IMGN) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *